Tomorrows, a global health technology company that connects patients and physicians with pre-approval treatments, today published a new data report, entitled Searching for solutions: How physicians ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug.

A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising ...

Three exercises could serve as promising alternatives to traditional insomnia treatment routes and help you sleep better, a ...

As measles cases surge to record levels in the U.S., Health and Human Services Secretary Robert F. | As measles cases surge ...

A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising concerns that some treatments may be fast-tracked for approval without ...

Scientists have used AI to re-analyse a clinical trial for an Alzheimer's medicine, and identified a group of patients who responded to treatment. The ...

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials.

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives, namely ...